Stereotaxis (Stereotaxis) Debt-to-Equity

: 0.25 (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

Stereotaxis's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.43 Mil. Stereotaxis's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.06 Mil. Stereotaxis's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $21.92 Mil. Stereotaxis's debt to equity for the quarter that ended in Dec. 2023 was 0.25.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Stereotaxis's Debt-to-Equity or its related term are showing as below:

STXS' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.47 Med: 0.15 Max: 0.25
Current: 0.25

During the past 13 years, the highest Debt-to-Equity Ratio of Stereotaxis was 0.25. The lowest was -1.47. And the median was 0.15.

STXS's Debt-to-Equity is ranked worse than
54.61% of 716 companies
in the Medical Devices & Instruments industry
Industry Median: 0.2 vs STXS: 0.25

Stereotaxis Debt-to-Equity Historical Data

The historical data trend for Stereotaxis's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stereotaxis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.15

0.11

0.16

0.18

0.25

Stereotaxis Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.18	0.20	0.21	0.23	0.25

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Stereotaxis's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stereotaxis Debt-to-Equity Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Stereotaxis's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Stereotaxis's Debt-to-Equity falls into.

Stereotaxis Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Stereotaxis's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.428	+	5.062)	/	21.92
	=	0.25

Stereotaxis's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.428	+	5.062)	/	21.92
	=	0.25

Stereotaxis (AMEX:STXS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Stereotaxis Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Stereotaxis's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Stereotaxis (Stereotaxis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stereotaxis Inc (AMEX:STXS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

RJR1:Germany

Address

710 North Tucker Boulevard, Suite 110, St. Louis, MO, USA, 63101

Website

https://www.stereotaxis.com

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service and accessories stream. The company generates the majority of revenue from the United States.

Executives

Paul J Isaac	10 percent owner	530 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10036
Myriam Curet	director	1020 KIFER ROAD, SUNNYVALE CA 94086
David Benfer	director	5 SELDEN AVENUE, BRANFORD CT 06404
Kimberly R. Peery	officer: Chief Financial Officer	C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE: SUITE 100, ST. LOUIS MO 63108
Kevin M. Barry	officer: Chief Legal Officer & Secretar	4320 FOREST PARK AVENUE, 100, ST. LOUIS MO 63108
Ross B Levin	director	530 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10036
Fariba Fischel Ghodsian	10 percent owner	10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Dafna Capital Management Llc	10 percent owner	10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
David Leo Fischel	director	10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Arun Swarup Menawat	director	2412 EIGHTH LINE, OAKVILLE A6 L6H6S9
Joe E Kiani	director	4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Paul Brathwaite	officer: VP Research & Development	C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Martin C Stammer	officer: Chief Financial Officer	C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Nathan Fischel	director	10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Duane Desisto	director	C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730